Amgen Started as an “Outperform” at BMO Capital; Valuation Call (AMGN)

Biotech giant Amgen, Inc. (AMGN) on Thursday saw its coverage initiated with an “Outperform” rating by analysts at BMO Capital.

The firm also set a $67 price target on AMGN shares, which suggests a 21% upside to the stock’s Wednesday closing price of $55.38.

BMO Capital noted AMGN shares look cheap at the moment, since they’re trading at less than 10x expected 2012 earnings.

Amgen shares were unchanged in premarket trading Thursday.

The Bottom Line
Shares of Amgen (AMGN) have a 2.02% dividend yield, based on last night’s closing stock price of $55.38. The stock has technical support in the $51-$53 price area. If the shares can firm up, we see overhead resistance around the $58 price level.

Amgen, Inc. (AMGN) is not recommended at this time, holding a DARS™ Rating of 3.1 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here